Molecular response of ≤10% BCR::ABL1IS is predictive of positive outcomes in patients with treatment-resistant chronic-phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 OPTIC trial Meeting Abstract
| Authors: | Apperley, J.; Cortes, J.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M.; Lipton, J. H.; Lomaia, E.; Maness, L.; Mauro, M.; McCloskey, J.; Moiraghi, B.; Pavlovsky, C.; Rojas, C.; Rousselot, P.; Sacha, T.; Talpaz, M.; Turkina, A.; Sutton, M. U.; Ren, X.; Vorog, A.; Rosti, G. |
| Abstract Title: | Molecular response of ≤10% BCR::ABL1IS is predictive of positive outcomes in patients with treatment-resistant chronic-phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 OPTIC trial |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | tki; ponatinib; bcr::abl1; cp-cml |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S339 |
| Language: | English |
| ACCESSION: | WOS:001062479600269 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01136-9 |
| Notes: | Meeting Abstract: CML-319 -- Source: Wos |
